OSUR — Stock Film
STOCK FILMSCENE 1/11OSUR · $3.25
Stock Expert AI presents
OSUR
OraSure Technologies, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
OraSure Technologies, Inc. What it actually does.

Develops and manufactures oral fluid diagnostic products. Offers rapid tests for infectious diseases like HIV, Hepatitis C, and Ebola. Now — the numbers.

on the stock market since 1986
500 employees
$223.8M market value
WHERE DOES THE MONEY COME FROM?
95%Product and Services
Product and ServicesOther Revenues 5%
95% of all revenue comes from a single line: Product and Services.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Revenue last year:
$115M
The loss that same year:
$68.7M
For every $1 it earns, the company spends $1.6.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 16% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$233.7M
2021
2022
2023
2024
$115M
2025
In the vault right now:
$199.3M
DEBT: $13.2M
At this pace, that money lasts about 2.9 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
39
weak

Clearly below the class average.

FINANCIAL STRENGTH
56
average

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
81
very strong

The price looks reasonable next to what the company earns.

GROWTH
2
very weak

Clearly below the class average.

PRICE MOMENTUM
42
weak

Clearly below the class average.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $199.3M in the vault; even if every debt were paid off, $186.1M would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 25 buys and 12 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $68.7M against $115.0M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 2/100.

3
THE RISKS · 3/3
The business trails its class

Measured against its sector, the quality of the business sits below the class average. Report-card grade: 39/100.

FINALE · THE GRADE
D
31 / 100 · MoonshotScore

On our five-subject report card, OSUR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: OSUR’s sales are going backwards, and it closed last year at a loss. The road back runs through both.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film